CL2020002915A1 - Composiciones para el tratamiento de condiciones de la piel - Google Patents
Composiciones para el tratamiento de condiciones de la pielInfo
- Publication number
- CL2020002915A1 CL2020002915A1 CL2020002915A CL2020002915A CL2020002915A1 CL 2020002915 A1 CL2020002915 A1 CL 2020002915A1 CL 2020002915 A CL2020002915 A CL 2020002915A CL 2020002915 A CL2020002915 A CL 2020002915A CL 2020002915 A1 CL2020002915 A1 CL 2020002915A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- treatment
- skin
- metabolites
- skin conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En el presente documento se describen métodos y composiciones para el tratamiento de las condiciones de la piel asociadas a la disbiosis. En el presente documento se describe además el uso de metabolitos para el tratamiento de la microbiota desregulada en un Sujeto. Dichos metabolitos pueden ser producidos por microorganismos presentes en mayor abundancia en la piel de los Sujetos sanos en comparación con la piel de un Sujeto que tiene disbiosis de la piel. Además, las composiciones y métodos proporcionados en este documento describen el uso de Metabolitos como parte de una terapia de combinación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862670341P | 2018-05-11 | 2018-05-11 | |
US201862703737P | 2018-07-26 | 2018-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002915A1 true CL2020002915A1 (es) | 2021-04-30 |
Family
ID=68465006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002915A CL2020002915A1 (es) | 2018-05-11 | 2020-11-10 | Composiciones para el tratamiento de condiciones de la piel |
Country Status (13)
Country | Link |
---|---|
US (2) | US10973841B2 (es) |
EP (1) | EP3790563A4 (es) |
JP (1) | JP2021523900A (es) |
KR (1) | KR20210013080A (es) |
CN (1) | CN113194969A (es) |
BR (1) | BR112020023050A2 (es) |
CA (1) | CA3099903A1 (es) |
CL (1) | CL2020002915A1 (es) |
GB (1) | GB2588721A (es) |
MX (1) | MX2020012018A (es) |
SG (1) | SG11202011188SA (es) |
WO (1) | WO2019217203A1 (es) |
ZA (1) | ZA202007055B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019513769A (ja) | 2016-04-19 | 2019-05-30 | ザ ユナイテッド ステイツ オブ アメリカ,アズ レプリゼンテッド バイ ザ セクレタリー,デパートメント オブ ヘルス アンド ヒューマン サービシーズ | アトピー性皮膚炎を処置するためのグラム陰性種の使用 |
US10293005B2 (en) | 2016-04-19 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
EP4000688A1 (en) | 2020-11-19 | 2022-05-25 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of trenbolone acetate having a definite particle size distribution |
EP4001288A1 (en) | 2020-11-19 | 2022-05-25 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of trenbolone acetate having a definite particle size distribution and a irregular hexagon plates crystal habit |
EP4001289B1 (en) | 2020-11-19 | 2023-05-03 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of trenbolone and/or trenbolone acetate |
CN115927128B (zh) * | 2023-03-10 | 2023-05-09 | 广州优科生物科技有限公司 | 一种透明颤菌发酵产物及其制备方法与应用 |
CN116139163B (zh) * | 2023-03-22 | 2023-09-05 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 一种粘液玫瑰单胞菌胞外多糖在制备用于缓解特应性皮炎的药物上的应用 |
CN116617269A (zh) * | 2023-05-17 | 2023-08-22 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 粘液玫瑰单胞菌活菌制剂及胞外多糖在制备用于缓解uvb导致的皮肤损伤的药物中的应用 |
CN116531310B (zh) * | 2023-05-18 | 2023-12-22 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 粘液玫瑰单胞菌及其胞外多糖在制备用于改善皮肤状况产品中的应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US4829000A (en) | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
SK280222B6 (sk) | 1993-10-22 | 1999-10-08 | Smithkline Beecham Corporation | Farmaceutický alebo veterinárny prostriedok |
ATE356630T1 (de) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
WO2003011261A1 (en) | 2001-08-01 | 2003-02-13 | Medlogic Global Limited | Cyanoacrylate monomer-containing antibiotic formulation for topical use |
US20030100034A1 (en) * | 2001-10-16 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | 9136, a human aldehyde dehydrogenase family member and uses therefor |
DE10158712A1 (de) | 2001-11-29 | 2003-06-26 | Umwelttechnik Georg Fritzmeier | Zusammensetzung zur Behandlung der Hautoberfläche |
ZA200604768B (en) * | 2003-11-11 | 2007-10-31 | Veckis Ind Ltd | Disinfecting composition and methods of making and using same |
EP1786445B1 (en) | 2004-08-25 | 2011-06-08 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Live microbial microbicides |
JP2006131622A (ja) | 2004-10-05 | 2006-05-25 | Genichiro Soma | 薬剤 |
KR20070091613A (ko) | 2004-11-08 | 2007-09-11 | 그렌마크 파머수티칼스 엘티디. | 항여드름 화합물 및 항생제 화합물을 함유하는 국소적 제약조성물 |
EP1736537A1 (en) | 2005-06-22 | 2006-12-27 | OrganoBalance GmbH | Methods and means for protecting the skin against pathogenic microorganisms |
FR2942719B1 (fr) | 2009-03-04 | 2011-08-19 | Oreal | Utilisation de microorganismes probiotiques pour limiter les irritations cutanees |
AU2010268647B2 (en) | 2009-06-30 | 2015-01-15 | Derman Biomedicine Co. Ltd. | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
EP2465507A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating skin diseases |
DK2704704T3 (en) | 2011-05-03 | 2019-01-14 | Dupont Nutrition Biosci Aps | PROBIOTIC BACTERIES FOR TOPICAL TREATMENT OF SKIN DISORDERS |
US20130121968A1 (en) | 2011-10-03 | 2013-05-16 | Atossa Genetics, Inc. | Methods of combining metagenome and the metatranscriptome in multiplex profiles |
EP2836224A4 (en) | 2012-02-29 | 2015-12-16 | Ethicon Endo Surgery Inc | COMPOSITIONS OF BIOZOOSE AND RELATED METHODS |
GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
US9956282B2 (en) | 2013-12-16 | 2018-05-01 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
CA2946050C (en) | 2014-04-15 | 2023-08-29 | Aobiome Llc | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
US9526201B2 (en) | 2015-01-05 | 2016-12-27 | Cnh Industrial America Llc | Twin-row planter with tandem driven seed meters |
EP3285872A4 (en) | 2015-04-20 | 2019-02-20 | S-Biomedic NV | METHODS AND COMPOSITIONS FOR MODIFYING THE COMPOSITION OF THE SKIN MICROBIOMA USING COMPLEX MIXTURES OF BACTERIAL STRAINS |
JP2018522878A (ja) * | 2015-07-02 | 2018-08-16 | エーオーバイオーム, エルエルシー.AOBiome, LLC. | マイクロバイオーム適合化粧品 |
JP2019513769A (ja) | 2016-04-19 | 2019-05-30 | ザ ユナイテッド ステイツ オブ アメリカ,アズ レプリゼンテッド バイ ザ セクレタリー,デパートメント オブ ヘルス アンド ヒューマン サービシーズ | アトピー性皮膚炎を処置するためのグラム陰性種の使用 |
US10293005B2 (en) | 2016-04-19 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
AU2017254684A1 (en) * | 2016-04-21 | 2018-12-06 | Weiss Bioscience, Inc. | Compositions and methods for treatment of skin disorders |
WO2018049556A1 (en) * | 2016-09-13 | 2018-03-22 | The Procter & Gamble Company | Methods of increasing microbial diversity of a skin microbiota |
US10695386B2 (en) | 2017-05-11 | 2020-06-30 | Shayne K. Morris | Skin microbiome colonizer formulations and methods for use |
BR112021001206A2 (pt) | 2018-07-23 | 2021-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | uso de espécies gram negativas para tratar dermatite atópica |
-
2019
- 2019-05-02 US US16/401,986 patent/US10973841B2/en active Active
- 2019-05-02 JP JP2020563598A patent/JP2021523900A/ja active Pending
- 2019-05-02 BR BR112020023050-2A patent/BR112020023050A2/pt not_active Application Discontinuation
- 2019-05-02 CA CA3099903A patent/CA3099903A1/en not_active Abandoned
- 2019-05-02 EP EP19799032.8A patent/EP3790563A4/en not_active Withdrawn
- 2019-05-02 SG SG11202011188SA patent/SG11202011188SA/en unknown
- 2019-05-02 GB GB2017977.6A patent/GB2588721A/en not_active Withdrawn
- 2019-05-02 KR KR1020207035626A patent/KR20210013080A/ko unknown
- 2019-05-02 MX MX2020012018A patent/MX2020012018A/es unknown
- 2019-05-02 WO PCT/US2019/030444 patent/WO2019217203A1/en unknown
- 2019-05-02 CN CN201980046526.4A patent/CN113194969A/zh active Pending
-
2020
- 2020-11-10 CL CL2020002915A patent/CL2020002915A1/es unknown
- 2020-11-12 ZA ZA2020/07055A patent/ZA202007055B/en unknown
-
2021
- 2021-02-25 US US17/185,734 patent/US20210186998A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190343856A1 (en) | 2019-11-14 |
EP3790563A4 (en) | 2022-03-23 |
GB202017977D0 (en) | 2020-12-30 |
GB2588721A (en) | 2021-05-05 |
SG11202011188SA (en) | 2020-12-30 |
MX2020012018A (es) | 2021-03-02 |
CA3099903A1 (en) | 2019-11-14 |
US20210186998A1 (en) | 2021-06-24 |
KR20210013080A (ko) | 2021-02-03 |
US10973841B2 (en) | 2021-04-13 |
BR112020023050A2 (pt) | 2021-03-16 |
WO2019217203A1 (en) | 2019-11-14 |
CN113194969A (zh) | 2021-07-30 |
ZA202007055B (en) | 2022-08-31 |
JP2021523900A (ja) | 2021-09-09 |
EP3790563A1 (en) | 2021-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002915A1 (es) | Composiciones para el tratamiento de condiciones de la piel | |
UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
CL2016002992A1 (es) | Combinación, composición y método de administración de la combinación o composición a animales | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
CL2017001893A1 (es) | Uso de prg4 como agente antiinflamatorio | |
CL2021000415A1 (es) | Vesículas derivadas de lactobacillus paracasei y uso de las mismas | |
BR112017008344A2 (pt) | extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica. | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
BR112017008726A2 (pt) | usos de um extrato de fermento e de um exopolissacarídeo, e, composição cosmética. | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CL2020000463A1 (es) | Compuestos espirocíclicos y sus métodos de preparación y uso. | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
AR107967A1 (es) | Ácido hialurónico modificado, método para su preparación y usos del mismo | |
BR112017014361A2 (pt) | métodos para aperfeiçoamento de terapia celular | |
NI202000014A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
CL2011002675A1 (es) | Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. | |
CR20160316A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
CL2018001913A1 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
AR122352A1 (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este | |
CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
BR112018069682A2 (pt) | métodos de tratamento para doenças colestáticas e fibróticas | |
CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia |